Sign In
Buy TARS
$58.76
+1.35 (+2.35%)
At Close: Jun 03, 2026
Wall Street Analysts Think Tarsus Pharmaceuticals (TARS) Could Surge 26.98%: Read This Before Placing a Bet
10:56am, Wednesday, 04'th Dec 2024
The consensus price target hints at a 27% upside potential for Tarsus Pharmaceuticals (TARS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earni
Wall Street Analysts Believe Tarsus Pharmaceuticals (TARS) Could Rally 41.09%: Here's is How to Trade
11:00am, Monday, 18'th Nov 2024
The average of price targets set by Wall Street analysts indicates a potential upside of 41.1% in Tarsus Pharmaceuticals (TARS). While the effectiveness of this highly sought-after metric is questiona
Tarsus Pharmaceuticals, Inc. (TARS) Q3 2024 Earnings Call Transcript
10:23pm, Wednesday, 13'th Nov 2024
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants David Nakasone - Head, IR Bobby Azamian - Chairman & CEO Aziz Mottiwala -
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Tops Revenue Estimates
06:31pm, Wednesday, 13'th Nov 2024
Tarsus Pharmaceuticals, Inc. (TARS) came out with a quarterly loss of $0.61 per share versus the Zacks Consensus Estimate of a loss of $0.90. This compares to loss of $1.28 per share a year ago.
Tarsus Welcomes Kate Goodrich, M.D., MHS, to its Board of Directors
08:30am, Wednesday, 13'th Nov 2024
Humana CMO brings more than two decades of experience driving innovative, value-based initiatives designed to improve patient outcomes
Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:00am, Thursday, 07'th Nov 2024
Tarsus Pharmaceuticals (TARS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tarsus to Report Third Quarter 2024 Financial Results on Wednesday, November 13, 2024
04:30pm, Wednesday, 06'th Nov 2024
IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tre
Tarsus Appoints Elizabeth Yeu, M.D., as Chief Medical Officer
08:30am, Tuesday, 05'th Nov 2024
Dr. Yeu transitions from her role as Chief Medical Advisor and Board Member to lead the Company's newly created Medical Organization Dr. Yeu transitions from her role as Chief Medical Advisor and Boar
Tarsus Pharmaceuticals (TARS) Surges 10.6%: Is This an Indication of Further Gains?
07:41am, Wednesday, 30'th Oct 2024
Tarsus Pharmaceuticals (TARS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further streng
Tarsus Launches “Your Mitey Problem,” the First Direct-to-Consumer TV Campaign for XDEMVY® (lotilaner ophthalmic solution) 0.25%
08:30am, Thursday, 17'th Oct 2024
Campaign showcases root cause of Demodex blepharitis through creative representation of mischief-causing mites on patients' eyelids
Tarsus to Participate in Fireside Chat at UBS Virtual Ophthalmology Day 2024
05:00pm, Wednesday, 25'th Sep 2024
IRVINE, Calif., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tr
Tarsus Pharmaceuticals: Unlocking Growth Potential With Eye Care Innovations
03:17pm, Friday, 20'th Sep 2024
Tarsus Pharmaceuticals, Inc.'s Xdemvy, the first FDA-approved treatment for demodex blepharitis, has shown significant efficacy and rapid revenue growth, with $40.8M revenue in Q2 2024. The company is
Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference
05:00pm, Wednesday, 28'th Aug 2024
IRVINE, Calif., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Tarsus Pharmaceuticals, Inc. (NASDAQ: TARS), whose mission is to focus on unmet needs and apply proven science and new technology to revolutionize tre
Tarsus Pharmaceuticals: Strong Execution In Eye Disease Treatment
04:56pm, Tuesday, 20'th Aug 2024
Tarsus Pharma has a drug for Demodex blepharitis and multiple late-stage assets in its pipeline, including lotilaner for various formulations. The company has seen a 65% increase in stock value, with
Tarsus Pharmaceuticals, Inc. (TARS) Q2 2024 Earnings Call Transcript
01:50pm, Saturday, 10'th Aug 2024
Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS ) Q2 2024 Earnings Conference Call August 8, 2024 4:30 PM ET Company Participants David Nakasone - Head, Investor Relations Bobby Azamian - Chairman and CEO A
